In the LoDoCo2 phase III trial, low-dose colchicine reduced cardiovascular events in chronic coronary disease; it was approved by the FDA in 2023 for cardiovascular prevention.
Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).